Friday-Sunday, February 28 – March 2, 2025, Miami, Florida

Fourth Annual National General Medical Oncology Summit

A Multitumor CME/MOC-, NCPD- and ACPE-Accredited Educational Conference Developed in Partnership with Florida Cancer Specialists & Research Institute

Register for in-person Register for webcast

Dates
Friday to Sunday
February 28 to March 2, 2025

Location
Fontainebleau Miami Beach
4441 Collins Ave
Miami Beach, Florida
Hotel Phone: (305) 535-3283 or toll free (800) 548-8886

Meeting Room
Glimmer Ballroom – Fourth Floor

Room Reservations
A special discounted room rate of $399 (plus applicable tax and discounted resort fee) is available to conference attendees at Fontainebleau Miami Beach. Please see the Location tab for details.

Note from the Moderator

This coming February 28th marks the return of our annual National General Medical Oncology Summit. To add community perspectives, we are pleased to be partnering again with Florida Cancer Specialists & Research Institute for this one-of-a-kind offering that will span 3 days and feature a stellar multidisciplinary faculty panel of clinical investigators and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. The conference’s educational design and the topics that will be discussed offer interested clinicians access to the in-depth perspectives of some of the top minds in the field regarding significant new datasets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with cancer. We hope you will join us in sunny South Florida for a learning experience unlike any other out there.



FACULTY

Biliary Tract Cancers
Mitesh J Borad, MD
Professor of Medicine
Mayo Clinic College of Medicine and Science
Getz Family Professor of Research
Mayo Clinic Arizona
Program Leader, Novel Therapeutics and Therapeutic Modalities Program
Mayo Clinic Comprehensive Cancer Center
Phoenix, Arizona

James J Harding, MD
Associate Attending
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York


Bladder Cancer
Shilpa Gupta, MD
Clinical Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Director, Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio

Jonathan E Rosenberg, MD
Chief, Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W Ercklentz Chair
Memorial Sloan Kettering Cancer Center
New York, New York


Breast Cancer
Aditya Bardia, MD, MPH
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Virginia F Borges, MD, MMSc
Professor of Medicine with Tenure
Robert F and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer Research
Deputy Head, Division of Medical Oncology
Director, Breast Cancer Research Program and
Young Women’s Breast Cancer
Translational Program
University of Colorado Cancer Center
Aurora, Colorado

Harold J Burstein, MD, PhD
Institute Physician
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas


Chronic Lymphocytic Leukemia
Nicole Lamanna, MD
Judy Horrigan Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Leukemia Service, Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Irving Medical Center
New York, New York

Kerry A Rogers, MD
Associate Professor
Division of Hematology
The Ohio State University
Columbus, Ohio


Colorectal Cancer
Christopher Lieu, MD
Professor of Medicine
Associate Director for Clinical Research
Co-Director, GI Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado

Kanwal Raghav, MD
Associate Professor
Gastrointestinal Medical Oncology
Executive Medical Director (EMD)
Ambulatory Treatment Centers
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Gastroesophageal Cancer
Yelena Y Janjigian, MD
Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Samuel J Klempner, MD
Associate Professor
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts


Gynecologic Cancers
David M O'Malley, MD
Director and Professor
Division of Gynecologic Oncology in
Obstetrics and Gynecology
John G Boutselis Chair in Gynecologic Oncology
The Ohio State University and The James Comprehensive Cancer Center
Columbus, Ohio

Additional faculty to be announced.






Hepatocellular Carcinoma
Thomas A Abrams, MD
Institute Physician
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Director, Liver Tumor Center
Boston, Massachusetts

Ahmed Omar Kaseb, MD, CMQ
John E and Dorothy J Harris Professor in Gastrointestinal Cancer Research
Member, National Hepatobiliary Task
Force NCI, USA
Tenured Professor and Director, Hepatocellular Carcinoma Program
Director, MD Anderson HCC SPORE
Editor-in-Chief, Journal of Hepatocellular Carcinoma
Department of Gastrointestinal Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Lung Cancer (EGFR Mutation-Positive Non-Small Cell Lung Cancer)
Jonathan Goldman, MD
Professor of Medicine
UCLA Hematology and Oncology
Director of Clinical Trials in Thoracic Oncology
Associate Director of Drug Development
UCLA Health
Santa Monica, California

Natasha B Leighl, MD, MMSc (Clin Epi)
Professor, Department of Medicine
Adjunct Professor, IHPME, Dalla Lana School
of Public Health
University of Toronto
OSI Pharmaceuticals Foundation Chair in New Cancer Drug Development
Thoracic Oncology Lead, Division of Medical Oncology
Princess Margaret Cancer Center
Toronto, Ontario


Lung Cancer (Immunotherapy and Other Nontargeted Approaches)
Stephen V Liu, MD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Additional faculty to be announced.


Multiple Myeloma
Natalie S Callander, MD
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Thomas Martin, MD
Associate Chief, Hematology/Oncology
Director, Hematology, Blood and Marrow Transplantation and Cell Therapy
Helen Diller Family Comprehensive Cancer Center
UCSF Medical Center
San Francisco, California


Neuroendocrine Tumors
Simron Singh, MD, MPH
Professor, University of Toronto
Susan Leslie Clinic for Neuroendocrine Tumours
Odette Cancer Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Jonathan Strosberg, MD
Professor
Moffitt Cancer Center and Research Institute
Tampa, Florida


Non-Hodgkin Lymphoma
Christopher Flowers, MD, MS
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams
Distinguished University Chair in Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Krish Patel, MD
Director of Lymphoma Research
Sarah Cannon Research Institute
Nashville, Tennessee


Prostate Cancer
Rahul Aggarwal, MD
Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
Director, Genitourinary Medical Oncology
University of California, San Francisco
Department of Medicine
Division of Hematology/Oncology
Associate Director for Clinical Research
UCSF Helen Diller Family
Comprehensive Cancer Center
San Francisco, California

William K Oh, MD
Clinical Professor of Medicine
Division of Hematology and Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York


Sarcoma and Other Soft Tissue Disorders
Richard F Riedel, MD
Professor of Medicine
Duke Cancer Institute
Duke University
Durham, North Carolina

Additional faculty to be announced.


MODERATOR
Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Lilly, Merck, SpringWorks Therapeutics Inc, and Stemline Therapeutics Inc.

Friday to Sunday, February 28 – March 2, 2025

Topics and schedule are subject to change. Times indicated are eastern time.

Friday, February 28, 2025
6:30 PM – 7:00 PM Registration and Welcome Reception
7:00 PM – 9:00 PM Keynote Session: Hormone Receptor-Positive Metastatic Breast Cancer
 
Saturday, March 1, 2025
7:00 AM – 7:45 AM Breakfast
7:45 AM – 9:25 AM Module 1: HER2-Positive, Triple-Negative and Localized Breast Cancer
9:25 AM – 9:45 AM Morning Break
9:45 AM – 10:35 AM Module 2: Neuroendocrine Tumors
10:35 AM – 11:25 AM Module 3: Chronic Lymphocytic Leukemia
11:25 AM – 12:15 PM Module 4: Sarcoma and Other Soft Tissue Disorders
12:15 PM – 1:00 PM Lunch Break
1:00 PM – 1:50 PM Module 5: EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
1:50 PM – 2:40 PM Module 6: Gynecologic Cancers
2:40 PM – 3:30 PM Module 7: Prostate Cancer
3:30 PM – 3:50 PM Afternoon Break
3:50 PM – 4:40 PM Module 8: Biliary Tract Cancers
4:40 PM – 5:30 PM Module 9: Non-Hodgkin Lymphoma
5:30 PM Adjourn
 
Sunday, March 2, 2025
Tentative Times The Sunday schedule will be finalized in the coming weeks.
 
7:00 AM – 7:45 AM Breakfast
7:45 AM – 3:30 PM Morning General Session
12:15 PM – 1:00 PM Lunch Break
1:00 PM – 3:30 PM Afternoon General Session

Topics to Be Covered
  • Colorectal Cancer
  • Gastroesophageal Cancer
  • Hepatocellular Carcinoma
  • Immunotherapy and Other Nontargeted Approaches for NSCLC
  • Multiple Myeloma
  • Urothelial Bladder Cancer
  • Additional topics to be announced.

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Effectively apply results of practice-changing clinical research to the care of patients with cancer.
  • Appraise the clinical relevance of recent pivotal cancer research published in peer-reviewed journals or presented at major oncology conferences.
  • Recall ongoing trials of therapies for select hematologic cancers and solid tumors, and appropriately refer patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Apply an awareness of new datasets and the perspectives of tumor-specific clinical investigators to refine or validate current treatment algorithms.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider the implications for clinical practice.

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 14.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 14.75 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statement
This educational activity for 14.75 contact hours is provided by Research To Practice.

This activity is awarded 14.75 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Education provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.1475 CEU (14.75 contact hours) of continuing education credit. To receive 14.75 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of a CME/NCPD accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer (physician for CME, nurse for NCPD) for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Aggarwal, Dr Burstein, Dr Leighl and Dr Lieu have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Abrams — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, HistoSonics; Consulting Agreement: Elevar Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP. Dr Bardia — Consulting Agreements and Contracted Research: Alyssum Therapeutics, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Sanofi. Dr Borad — Advisory Committees: Elevar Therapeutics; Consulting Agreements: Guardant Health, Jazz Pharmaceuticals Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Biond Biologics, Dragonfly Therapeutics, Eisai Inc, Elevation Oncology, Incyte Corporation, Kinnate Biopharma, Nuvectis Pharma Inc, Pfizer Inc, Relay Therapeutics, Revolution Medicines, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC; Data and Safety Monitoring Boards/Committees: Accession Therapeutics. Dr Borges — Advisory Committees: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Consulting Agreements: Gilead Sciences Inc, Olema Oncology; Cofounder, Stock Interest (Private Company): Pearl Scientific LLC; Contracted Research: Agendia Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Gilead Sciences Inc, Olema Oncology, Pfizer Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: Pfizer Inc, Seagen Inc (HER2CLIMB-02 trial). Dr Flowers — Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation. Dr Goldman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Gritstone bio, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Advaxis Inc,AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, Spectrum Pharmaceuticals Inc, Vaccinex Inc. Dr Gupta — Advisory Committees: Acrivon Therapeutics, Bristol Myers Squibb, Merck, Seagen Inc; Consulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, EMD Serono Inc, Foundation Medicine, Gilead Sciences Inc, Guardant Health, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Acrivon Therapeutics, Bristol Myers Squibb, Merck, Novartis, QED Therapeutics, Roche Laboratories Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: Protara Therapeutics; Speakers Bureaus: Bristol Myers Squibb, Gilead Sciences Inc, Seagen Inc; Stock Options/Stock — Public Companies: BioNTech SE, Moderna, Nektar Therapeutics. Dr Harding — Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Jazz Pharmaceuticals Inc, Merck, RayzeBio Inc, Servier Pharmaceuticals LLC, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Codiak BioSciences, Jazz Pharmaceuticals Inc, Kinnate Biopharma, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Zymeworks Inc; Data and Safety Monitoring Board/Committee: Merck. Dr Janjigian — Advisory Committees: AbbVie Inc, AmerisourceBergen, Arcus Biosciences, ARS Pharmaceuticals, AskGene Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, eChinaHealth, Eisai Inc, Geneos Therapeutics, GSK, Guardant Health, HC Wainwright & Co, Imugene, Inspirna, Lilly, Lynx Health, Merck, Merck Serono, Mersana Therapeutics Inc, PeerMD, Pfizer Inc, Sanofi, Seagen Inc, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co Ltd, Zymeworks Inc; Contracted Research: Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Genentech, a member of the Roche Group, Inspirna, Lilly, Merck, Transcenta; Stock Options — Private Companies: Inspirna; Nonrelevant Financial Relationships: Clinical Care Options, Cycle for Survival, ED Medresources Inc, Fred’s Team, Imedex, Master Clinician Alliance, MJH Life Sciences, National Cancer Institute, Paradigm Medical Communications, PeerView Institute, Physician Education Resource (PER), Stand Up 2 Cancer, Talem Health, TotalCME, US Department of Defense, Veda Life Sciences Inc (stock options), WebMD. Dr Kaseb — Advisory Committees, Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc. Dr Lamanna — Advisory Committees: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Lilly, MingSight Pharmaceuticals, Octapharma, Oncternal Therapeutics. Dr Liu — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals; Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Guardant Health, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Merus, Mirati Therapeutics Inc, Natera Inc, Novartis, OSE Immunotherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc, Yuhan Corporation; Contracted Research: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Cogent Biosciences, Duality Biologics, Elevation Oncology, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma Biotechnology Inc, RAPT Therapeutics, Synthekine, SystImmune Inc. Dr Martin — Consulting Agreements: GSK, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bristol Myers Squibb, Johnson & Johnson Pharmaceuticals, Sanofi; Data and Safety Monitoring Board/Committee: Lilly. Dr Oh — Advisory Committees: Pfizer Inc; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Cytogen Corporation, Nature's Toolbox, Inc, Novartis, Sumitomo Dainippon Pharma Oncology Inc; Stock Options — Private Companies: Nature’s Toolbox, Inc; Stock Options/Stock — Public Companies: GeneDx. Dr O'Malley — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics, Duality Biologics, GSK, Merck, MSD, OncoC4, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Verastem Inc; Contracted Research: AbbVie Inc, Adaptimmune, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Atossa Therapeutics, BeiGene Ltd, Bristol Myers Squibb, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals Inc, Duality Biologics, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Exelixis Inc, Genelux Corporation, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Imvax Inc, Incyte Corporation, InterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Laekna Therapeutics, Leap Therapeutics Inc, Luzsana Biotechnology, Merck, Mersana Therapeutics Inc, MSD, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, OncoC4, Onconova Therapeutics Inc, OncoQuest Inc, Pfizer Inc, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, R-Pharm US, Rubius Therapeutics, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Sutro Biopharma, Tarveda Therapeutics, Tesaro, A GSK Company, Toray Industries Inc, Trillium Therapeutics Inc, Umoja Biopharma, VBL Therapeutics, Verastem Inc, Vincerx Pharma, Xencor, Zentalis Pharmaceuticals; Nonrelevant Financial Relationships: Amarex Clinical Research, GOG Foundation, Ludwig Institute for Cancer Research Ltd, National Cancer Institute, NRG Oncology, RTOG Foundation, SWOG. Dr O'Shaughnessy — Advisory Committees and Consulting Agreements: Agendia Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Byondis, Caris Life Sciences, Daiichi Sankyo Inc, DAVA Oncology, Eisai Inc, Exact Sciences Corporation, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Merck, Mersana Therapeutics Inc, Novartis, Ontada, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Tempus, Veru Inc. Dr Patel — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Lilly, Merck, Nurix Therapeutics Inc, Pfizer Inc; Contracted Research (Funding to Institution): AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Century Therapeutics, CRISPR Therapeutics, Fate Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Lilly, Merck, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sana, Xencor. Dr Raghav — Advisory Committees and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Pfizer Inc. Dr Rogers — Advisory Committees: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, Alpine Immune Sciences, BeiGene Ltd, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis. Dr Rosenberg — Advisory Committees: Astellas, Seagen Inc, Tyra Biosciences Inc; Consulting Agreements: Aadi Bioscience, Aktis Oncology, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Generate Biomedicines, Gilead Sciences Inc, Hengrui Therapeutics Inc, Imvax Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc, Samsung Bioepis, Seagen Inc, Tyra Biosciences Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc. Dr Singh — Advisory Committees: Ipsen Biopharmaceuticals Inc, Novartis. Dr Strosberg — Advisory Committees: Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc; Contracted Research: ITM Isotope Technologies Munich SE, RadioMedix Inc, RayzeBio Inc. Additional faculty to be announced.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME/NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Lilly, Merck, SpringWorks Therapeutics Inc, and Stemline Therapeutics Inc.

Fontainebleau Miami Beach
4441 Collins Ave
Miami Beach, FL 33140
Hotel phone: (305) 535-3283 or toll free (800) 548-8886

Meeting Room
Glimmer Ballroom – Fourth Floor

Room Reservations
A special discounted room rate of $399 per night and discounted resort fee of $42 per guest, per night, plus applicable taxes are available to conference attendees at the Fontainebleau Miami Beach hotel.

Instructions on how to secure hotel accommodations will be included in the confirmation email after you have completed registration.

Room reservations must be made by Tuesday, February 4, 2025. A limited number of rooms are available, and we encourage you to make your reservations early. After Tuesday, February 4, the hotel will offer the best rates based on room availability.

Parking

  • Overnight valet parking: A charge of $55 to $70 plus tax per car, per night, will apply. Pricing is based on availability.
  •  
  • Day rate valet parking: A charge of $35 to $50 plus tax per car will apply. Pricing is based on availability.
  •  
  • Self-parking is not available at the hotel.
  •  
  • Prices are subject to change.

Map

This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

In-Person Registration Fees
This event is free of charge for practicing physicians, fellows, pharmacists, nurses and other healthcare providers actively caring for patients with cancer.

DISCOUNTED RATE EXTENDED UNTIL FEBRUARY 10TH
For all other individuals, including industry professionals,* a conference registration fee of $1,150 is available through February 10, 2025 and then $1,400 after that day. All fees processed will be nonrefundable after 11:59 PM eastern time on February 10, 2025. To cancel your registration, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (305) 377-2828 or toll free at (800) 233-6153.

* Individuals employed by for-profit organizations, including financial institutions and biotech or pharmaceutical companies.

Please note, the conference registration fee includes access to book accommodations within the conference block at the discounted rate and access to all conference educational sessions and meal events. If you are interested in exhibiting, please email us at Meetings@ResearchToPractice.com.

There is no fee to attend the session virtually.

IN-PERSON Registration for clinicians in practice/healthcare professionals (Complimentary)

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »

There is no registration fee for clinicians in practice.

IN-PERSON Registration for other/industry professionals*

I am not a clinician treating patients.

IN-PERSON Registration
for nonclinicians »

Please note, a limited number of seats are available to other/industry professionals.

 
* Individuals employed by for-profit organizations, including financial institutions and biotech or pharmaceutical companies.
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.